Crucially, PXA’s molecular signature, characterized by MAPK pathway activation predominantly via BRAF V600E and the CDKN2A/B deletion, provides a robust tool to differentiate it from close differentials such as ganglioglioma. This evidence concerns the gene CDKN2A and ganglioglioma.